Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939610 | 1.00 | POLB (0.39) | POLBNPC1RAB9AMMP13KDM4E | |
| SCHEMBL30939516 | 0.96 | MMP13 (0.36) | POLBNPC1RAB9AMMP13KDM4E | |
| SCHEMBL9901051 | 0.96 | MMP13 (0.36) | POLBNPC1RAB9AMMP13KDM4E | |
| SCHEMBL30939546 | 0.91 | AR (0.42) | MMP13KDM4EMCOLN3ARALDH1A1 | |
| SCHEMBL9901069 | 0.91 | AR (0.42) | MMP13KDM4EMCOLN3ARALDH1A1 | |
| SCHEMBL19400287 | 0.84 | AR (0.41) | POLBMMP13KDM4EMCOLN3AR | |
| SCHEMBL9905038 | 0.84 | AR (0.41) | POLBMMP13KDM4EMCOLN3AR | |
| SCHEMBL9923882 | 0.80 | MMP13 (0.34) | MMP13KDM4EMCOLN3 | |
| SCHEMBL30939572 | 0.79 | AR (0.41) | ARALDH1A1 | |
| SCHEMBL9901048 | 0.79 | AR (0.41) | ARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649066-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | claimed |
| US-20250017925-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2025-01-16 | — | — | US | disclosed |
| US-11944623-B2 | Modulators of Kv3 channels to treat pain | AUTIFONY THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| EP-3386506-B1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220071998-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-03-10 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| EP-2649066-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| US-20150157631-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | US | disclosed |
| EP-2852588-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013175211-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-11-28 | — | — | WO | disclosed |
| EP-2649066-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | POLB 4418/4885NPC1 1130/4885RAB9A 1403/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | POLB 4418/4885NPC1 1130/4885RAB9A 1403/4885 |
| US-11944623-B2 | Modulators of Kv3 channels to treat pain | KCNN3, KCNA3, KCND3 | POLB 4542/4885NPC1 2455/4885RAB9A 1493/4885 |
| US-20150157631-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | KCND3, KCNA3, KCNK3 | POLB 4349/4885NPC1 1119/4885RAB9A 2084/4885 |
| US-20220071998-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | POLB 4542/4885NPC1 2455/4885RAB9A 1493/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | POLB 4540/4885NPC1 1296/4885RAB9A 1463/4885 |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | POLB 4418/4885NPC1 1130/4885RAB9A 1403/4885 |
| US-20250017925-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | POLB 4542/4885NPC1 2455/4885RAB9A 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.